Daniel G. Stover

Dr. Daniel G. Stover

Auto-generated profile, based on publicly available information

Dr. Daniel G. Stover


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Lancet
Verified
Journal Article
Closed access
NKNicole M Kuderer
Nicole M Kuderer
TCToni K Choueiri
Toni K Choueiri
DSDimpy P Shah
Dimpy P Shah
YSYu Shyr
Yu Shyr
SRSamuel M Rubinstein
Samuel M Rubinstein
JWJack West
Jack West

6 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
VAViktor A. Adalsteinsson
Viktor A. Adalsteinsson
GHGavin Ha
Gavin Ha
SFSamuel S. Freeman
Samuel S. Freeman
ACAtish Choudhury
Atish Choudhury
DSDaniel G. Stover
Daniel G. Stover
MMMatthew Meyerson
Matthew Meyerson
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.

1 March 2019 in Cancer Cell
Verified
Journal Article
Closed access
YJYi-Zhou Jiang
Yi-Zhou Jiang
DMDing Ma
Ding Ma
CSChen Suo
Chen Suo
JSJinxiu Shi
Jinxiu Shi
MXMengzhu Xue
Mengzhu Xue
ZSZhi-Ming Shao
Zhi-Ming Shao

6 January 2016 in Nature
Verified
Journal Article
Open access
PDF file
SSShaokun Shu
Shaokun Shu
CLCharles Y. Lin
Charles Y. Lin
HHHousheng Hansen He
Housheng Hansen He
RWRobert M. Witwicki
Robert M. Witwicki
DTDoris P. Tabassum
Doris P. Tabassum
KPKornelia Polyak
Kornelia Polyak
BET inhibitors that target bromodomain chromatin readers such as BRD4 are being explored as potential therapeutics in cancer; here triple-negative breast cancer cell lines are shown to respond to BET inhibitors and resistance seems to be associated with transcriptional changes rather than drug efflux and mutations, opening potential avenues to improve clinical responses to BET inhibitors. BET inhibitors that target bromodomain chromatin readers such as BRD4 are being explored as potential therapeutics in cancer. Here Kornelia Polyak and colleagues investigate the response of breast cancer cell lines and xenograft mouse models to BET inhibitors. They find that triple-negative breast cancer cell lines respond to BET inhibitors. Resistance can emerge, but there is no evidence for mechanisms involving drug efflux or mutations in the bromodomain genes or known driver genes. Instead, there are transcriptional changes and increased recruitment of BRD4 to chromatin independent of its bromodomain, concomitant with its increased phosphorylation. Together with two recent Nature publications from the laboratories of Mark Dawson and Johannes Zuber dealing with different cancers, the study suggests potential avenues to improve clinical responses to BET inhibitors. Jeff Settleman discusses all three papers in News & Views. Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy1,2,3. BET bromodomain inhibitors, which have shown efficacy in several models of cancer4,5,6, have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs7,8,9. Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance.

1 September 2015 in Cell
Verified
Journal Article
Closed access
YWYubao Wang
Yubao Wang
TZTinghu Zhang
Tinghu Zhang
NKNicholas Kwiatkowski
Nicholas Kwiatkowski
BABrian J. Abraham
Brian J. Abraham
TLTong Ihn Lee
Tong Ihn Lee
JZJean J. Zhao
Jean J. Zhao

7 March 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BBBrian Bierie
Brian Bierie
SPSarah E. Pierce
Sarah E. Pierce
CKCornelia Kroeger
Cornelia Kroeger
DSDaniel G. Stover
Daniel G. Stover
PRPattabiraman Diwakar R
Pattabiraman Diwakar R
RWRobert A. Weinberg
Robert A. Weinberg
Neoplastic cells within individual carcinomas often exhibit considerable phenotypic heterogeneity in their epithelial versus mesenchymal-like cell states. Because carcinoma cells with mesenchymal features are often more resistant to therapy and may serve as a source of relapse, we sought to determine whether such cells could be further stratified into functionally distinct subtypes. Indeed, we find that a basal epithelial marker, integrin-β4 (ITGB4), can be used to enable stratification of mesenchymal-like triple-negative breast cancer (TNBC) cells that differ from one another in their relative tumorigenic abilities. Notably, we demonstrate that ITGB4+ cancer stem cell (CSC)-enriched mesenchymal cells reside in an intermediate epithelial/mesenchymal phenotypic state. Among patients with TNBC who received chemotherapy, elevated ITGB4 expression was associated with a worse 5-year probability of relapse-free survival. Mechanistically, we find that the ZEB1 (zinc finger E-box binding homeobox 1) transcription factor activity in highly mesenchymal SUM159 TNBC cells can repress expression of the epithelial transcription factor TAp63α (tumor protein 63 isoform 1), a protein that promotes ITGB4 expression. In addition, we demonstrate that ZEB1 and ITGB4 are important in modulating the histopathological phenotypes of tumors derived from mesenchymal TNBC cells. Hence, mesenchymal carcinoma cell populations are internally heterogeneous, and ITGB4 is a mechanistically driven prognostic biomarker that can be used to identify the more aggressive subtypes of mesenchymal carcinoma cells in TNBC. The ability to rapidly isolate and mechanistically interrogate the CSC-enriched, partially mesenchymal carcinoma cells should further enable identification of novel therapeutic opportunities to improve the prognosis for high-risk patients with TNBC. Significance It is widely appreciated that carcinoma cells exhibiting certain mesenchymal traits are enriched for cancer stem cells (CSCs) and can give rise to tumors with aggressive features. Whereas it has been proposed that mesenchymal carcinoma cell populations are internally heterogeneous, the field has made little progress in resolving the specific subtypes of mesenchymal carcinoma cells that pose the greatest risk for patients. We demonstrate the utility of integrin-β4 (ITGB4) in segregating these cells into distinct subpopulations with differing tumor-initiating abilities and pathological behaviors. In addition, we identified mechanistic links between ZEB1 (zinc finger E-box binding homeobox 1) and TAp63α (tumor protein 63 isoform 1) as regulators of ITGB4 expression and demonstrate that ITGB4 can be used as a marker to determine which patients are more likely to relapse after treatment.